<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292146</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000529</org_study_id>
    <nct_id>NCT03292146</nct_id>
  </id_info>
  <brief_title>Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study</brief_title>
  <official_title>Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to&#xD;
      investigate the effect of denosumab on BMD in women with anorexia nervosa. The investigators&#xD;
      hypothesize that 12 months of denosumab administration will result in an increase in bone&#xD;
      mineral density, decrease in markers of bone resorption and improvement in bone&#xD;
      microarchitecture in osteopenic women with anorexia nervosa compared with placebo.&#xD;
&#xD;
      An optional extension study will offer subjects 12-month administration of open-label&#xD;
      alendronate (an oral bisphosphonate) after the initial 12 month administration of denosumab&#xD;
      or placebo. We hypothesize that 12 months of denosumab followed by 12 months of open-label&#xD;
      alendronate will result in a greater increase in BMD compared to 12 months of placebo&#xD;
      followed by 12 months of open-label alendronate. Within the group of women who receive&#xD;
      sequential therapy with 12 months of denosumab followed by 12 months of alendronate, we&#xD;
      hypothesize that BMD will be maintained between 12 and 24 months while on alendronate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Actual">July 22, 2021</completion_date>
  <primary_completion_date type="Actual">July 22, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone density</measure>
    <time_frame>6 months, 12 months, and 24 months</time_frame>
    <description>Change in bone density</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bone Density</condition>
  <condition>Bone Loss</condition>
  <condition>Anorexia Nervosa</condition>
  <condition>Eating Disorder</condition>
  <condition>Atypical Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Active Denosumab 60mg Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60mg injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab 60 MG [Prolia]</intervention_name>
    <description>Denosumab 60mg injection at baseline and 6 months</description>
    <arm_group_label>Active Denosumab 60mg Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <description>Placebo Injection at baseline and 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate 70Mg Tab</intervention_name>
    <description>Alendronate 70mg PO weekly starting at Month 12 through 24 months.</description>
    <arm_group_label>Active Denosumab 60mg Injection</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age 20-60 years, skeletally mature with closed epiphyses&#xD;
&#xD;
          -  Anorexia nervosa or atypical anorexia nervosa defined by DSM-V diagnostic criteria&#xD;
&#xD;
          -  BMD T-score &lt; -1.0&#xD;
&#xD;
          -  Normal serum 25-OH vitamin D (&gt;30 ng/mL) and calcium levels&#xD;
&#xD;
          -  For women of reproductive age, agree to use an effective contraceptive method. Highly&#xD;
             effective methods of birth control include:&#xD;
&#xD;
               -  Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or&#xD;
                  skin patch)&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Intraduterine hormonal-releasing system (IUS)&#xD;
&#xD;
               -  Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion)&#xD;
&#xD;
               -  Your male partner has had a vasectomy and testing shows there is no sperm in the&#xD;
                  semen&#xD;
&#xD;
          -  Dental check up within the past year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's&#xD;
             or renal failure&#xD;
&#xD;
          -  Subjects with a known esophageal disease cannot participate in the alendronate&#xD;
             extension study&#xD;
&#xD;
          -  Any medication known to affect bone metabolism within 3 months of the study, excluding&#xD;
             oral contraceptives or other forms of estrogen administration. Bisphosphonates must&#xD;
             have been discontinued for at least one year before participation&#xD;
&#xD;
          -  Immunodeficiency or taking immunosuppressive therapy&#xD;
&#xD;
          -  Serum potassium &lt;3.0 meq/L&#xD;
&#xD;
          -  Serum ALT &gt;3 times upper limit of normal&#xD;
&#xD;
          -  eGFR of less than 30 ml/min&#xD;
&#xD;
          -  Hypocalcemia&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Active substance abuse, including alcohol&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Paget disease of bone&#xD;
&#xD;
          -  Osteomalacia&#xD;
&#xD;
          -  Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental&#xD;
             procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months),&#xD;
             poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Planned invasive dental procedure over the next 24 months.&#xD;
&#xD;
          -  Known senstivity to any of the products or components to be administered during dosing&#xD;
             or known sensitivity to mammalian cell derived drug products&#xD;
&#xD;
          -  Sensitivity to calcium or vitamin D supplements&#xD;
&#xD;
          -  Pregnant, planning to become pregnant with 7 months after the end of treatment and/or&#xD;
             breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Klahr Miller, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

